Table 3.

Polytomous logistic regression analysis of risk factors for serrated lesions by CIMP and BRAF mutation status clustered by participant: Group Health Enrollees 1998–2007

Serrated lesionsa by CIMP statusSerrated lesionsa by BRAF mutation status
Controls (n = 1,027)CIMP-negative (n = 311)CIMP-high (n = 108)Wild-type BRAF (n = 187)Mutant BRAF (n = 232)
%%ORb (95% CI)%ORb(95% CI)Pheterogeneityc%ORb (95% CI)%ORb (95% CI)Pheterogeneityc
Age (per year)nana0.99 (0.97–1.01)na1.03 (0.99–1.06)0.03na1.01 (0.99–1.03)na0.99 (0.97–1.01)0.27
Men40511.45 (1.06–1.97)471.10 (0.69–1.76)0.28491.21 (0.84–1.73)501.47 (1.04–2.09)0.46
Caucasian race86871.32 (0.85–2.04)932.27 (1.08–4.76)0.18891.50 (0.85–2.66)881.46 (0.91–2.35)0.97
Education
 High school or less15161.00111.00161.00141.00
 Some college25271.29 (0.80–2.07)231.70 (0.73–3.98)281.27 (0.73–2.19)261.46 (0.82–2.66)
 College graduate60571.09 (0.70–1.69)631.79 (0.81–3.89)0.15561.11 (0.67–1.83)601.34 (0.77–2.31)0.15
BMI, kg/m2
 <2541341.00371.00311.00381.00
 25–2938361.08 (0.76–1.52)371.08 (0.64–1.80)391.35 (0.89–2.06)330.90 (0.61–1.34)
 ≥3021301.78 (1.21–2.62)261.54 (0.86–2.73)0.62301.93 (1.21–3.09)291.57 (1.03–2.40)0.45
Regular NSAID use
 Never47511.00421.00481.00501.00
 Ever53490.71 (0.52–0.97)580.96 (0.60–1.53)0.24520.76 (0.52–1.11)500.77 (0.55–1.09)0.97
CRC family history22241.34 (0.94–1.88)180.86 (0.48–1.56)0.15221.22 (0.81–1.85)221.20 (0.80–1.80)0.98
Smoking status
 Never56401.00491.00361.00471.00
 Former39471.74 (1.28–2.37)431.16 (0.74–1.81)491.83 (1.44–2.42)441.47 (0.82–2.66)
 Current5134.41 (2.55–7.60)82.71 (1.19–6.18)0.07155.83 (3.18–10.71)92.75 (1.48–5.11)0.03
Prior polyps19261.44 (1.02–2.04)372.35 (1.46–3.79)0.07301.76 (1.17–2.63)281.60 (1.11–2.30)0.70
  • a419 serrated lesions among 359 participant clusters.

  • bAdjusted for all other factors in Table 2 and study phase.

  • cWald test P value comparing polyp case subtypes with one another.